Teva To Spend $200M On Labrys Biologics

Wed, 06/04/2014 - 8:11am

Teva Pharmaceutical Industries Ltd. plans to expand its lineup of migraine treatments by purchasing Labrys Biologics in a deal that could ultimately be worth more than $800 million.

The Israeli drugmaker said Tuesday that it will pay $200 million in cash up-front for the privately held drug developer and possibly an additional $625 million in milestone payments.

Labrys Biologics has no products on the market, but Teva cited the San Mateo, California, company's experimental drug for the prevention of chronic migraines as a key reason behind the deal. The drug, labeled LBR-101, is in midstage clinical testing.

Teva said the drug will complement the migraine treatment patch Zecuity that it acquired with the purchase of NuPathe Inc. Teva also is developing a potential abuse-resistant, extended-release version of the pain treatment hydrocodone.

U.S.-traded shares of Teva slipped 36 cents to $51.59 Tuesday morning, while the Standard & Poor's 500 index also fell slightly.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.